0000899243-20-007067.txt : 20200304
0000899243-20-007067.hdr.sgml : 20200304
20200304194904
ACCESSION NUMBER: 0000899243-20-007067
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200302
FILED AS OF DATE: 20200304
DATE AS OF CHANGE: 20200304
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Reed Joshua
CENTRAL INDEX KEY: 0001746541
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36332
FILM NUMBER: 20689154
MAIL ADDRESS:
STREET 1: C/O ALDEYRA THERAPEUTICS, INC.
STREET 2: 131 HARTWELL AVENUE, SUITE 320
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aldeyra Therapeutics, Inc.
CENTRAL INDEX KEY: 0001341235
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 131 HARTWELL AVENUE
STREET 2: SUITE 320
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 781-761-4904
MAIL ADDRESS:
STREET 1: 131 HARTWELL AVENUE
STREET 2: SUITE 320
CITY: LEXINGTON
STATE: MA
ZIP: 02421
FORMER COMPANY:
FORMER CONFORMED NAME: Aldexa Therapeutics, Inc.
DATE OF NAME CHANGE: 20130102
FORMER COMPANY:
FORMER CONFORMED NAME: Neuron Systems Inc
DATE OF NAME CHANGE: 20051012
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-03-02
0
0001341235
Aldeyra Therapeutics, Inc.
ALDX
0001746541
Reed Joshua
C/O ALDEYRA THERAPEUTICS, INC.
131 HARTWELL AVENUE
LEXINGTON
MA
02421
0
1
0
0
Chief Financial Officer
Common Stock
2020-03-02
4
A
0
250000
0.00
A
285774
D
Employee Stock Option (Right to Buy)
3.78
2020-03-02
4
A
0
137707
0.00
A
2030-03-01
Common Stock
137707
137707
D
Represents shares of common stock underlying a time-based restricted stock unit award (RSU). The RSU vests ratably in equal annual installments over a four-year period beginning on January 1, 2020, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date.
The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2020.
/s/ Joshua Reed
2020-03-04